TITLE:
Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review
AUTHORS:
Md. Imtiaz Hasan, Shahnaz Akter Shimu, Akhi Akther, Ishrat Jahan, Md. Hamiduzzaman, A. H. M. Nazmul Hasan
KEYWORDS:
Generic Drug, Reference Product, Pre-Formulation, NDA
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.9 No.10,
October
9,
2021
ABSTRACT: Development of generic drug product by pharmaceutical industry is a scientific and technical approach which is totally different from developing a reference or innovator product. Most of the developing countries focus on developing the generic drug products because huge amount of investment is required for innovation and to develop reference product. The generic medicine has to be bioequivalent to the innovator drug and ensure the same biological effect with proper safety and efficacy. Nowadays, the pharmaceutical industries focus on the development of generic product as this does not require that much time and cost compared to the innovator company. But development of generic product is also difficult as it contains the same therapeutic efficacy as innovator. The development approach is based on the target market, i.e. US market, EU market. If a manufacturer targets the US market, then all excipients should be USP grade, analysis should be conducted by USP method or in-house method and stability studies as well. Prior and during the development of generic drug product API selection, dosage form selection, reference product selection and characterization, formulation development, analytical method development, tech transfer or submission batch are prime concern. Then again, bioequivalence study, drug registration procedure and commercialization of the generic product considering regulatory guidance of respective regulatory agencies and the approaches taken by the regulatory agencies for the development of registration of generic medicines are also crucial as well for the development of generic drug product. The aim of this study was to review the entire stage of a generic drug development by a generic pharmaceutical company.